Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) from Schering-Plough Animal Health, Inc., to Medical Developments International, Ltd.
This rule is effective March 6, 2009.Start Further Info
FOR FURTHER INFORMATION CONTACT:
David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail: email@example.com.End Further Info End Preamble Start Supplemental Information
Schering-Plough Animal Health Corp., 556 Morris Ave., Summit, NJ 07901, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 14-485 for ANAFANE (methoxyflurane) Volatile Liquid for Inhalation Anesthesia to Medical Developments International, Ltd., P.O. Box 21, Sandown Village, 3171 VIC Australia.
Medical Developments International, Ltd., is not currently listed in the animal drug regulations as a sponsor of an approved application. In addition, FDA has noticed that this new animal drug has not been previously codified in 21 CFR part 529. Accordingly, the regulations are amended in 21 CFR 510.600(c) to add entries for Medical Developments International, Ltd., and in 21 CFR part 529 to add this new animal drug.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.Start List of Subjects Start Printed Page 9767
List of Subjects
- Administrative practice and procedure
- Animal drugs
- Reporting and recordkeeping requirements
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,End Amendment Part Start Part
PART 510—NEW ANIMAL DRUGSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part Start Amendment Part
2. In § 510.600, in the table in paragraph (c)(1) alphabetically add an entry for “Medical Developments International, Ltd.”; and in the table in paragraph (c)(2) numerically add an entry for “025245” to read as follows:End Amendment Part
(c) * * *
(1) * * *
|Firm name and address||Drug labeler code|
|* * * * *|
|Medical Developments International, Ltd.,P.O. Box 21, Sandown Village, 3171 VIC Australia||025245|
|* * * * *|
(2) * * *
|Drug labeler code||Firm name and address|
|* * * * *|
|025245||Medical Developments International, Ltd.,P.O. Box 21, Sandown Village, 3171 VIC Australia|
|* * * * *|
PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGSEnd Part Start Amendment Part
3. The authority citation forEnd Amendment Part Start Amendment Part
4. Add § 529.1455 to read as follows:End Amendment Part
(a) Specifications. Methoxyflurane liquid.
(b) Sponsor. See No. 025245 in § 510.600 of this chapter.
(c) Conditions of use—(1) Amount. The amount of methoxyflurane used depends on the weight of the patient, the depth of anesthesia, and the type of equipment used. Anesthesia may be induced with methoxyflurane alone, or by the intravenous administration of a short-acting general anesthetic or by inhalation of another anesthetic agent.
(2) Indications for use. For the induction and maintenance of general anesthesia.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dated: March 3, 2009.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.
[FR Doc. E9-4758 Filed 3-5-09; 8:45 am]
BILLING CODE 4160-01-S